August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Ed Shovelin: PDE Inhibitors Preferentially Affect ADP and TRAP6 Activation

Ed Shovelin/LinkedIn

Feb 9, 2026, 14:42

Ed Shovelin: PDE Inhibitors Preferentially Affect ADP and TRAP6 Activation

Ed Shovelin, Operations and Engineering Manager at Pplus Medical Limited, shared on LinkedIn:

”CRP-A by Pplus Medical Limited is increasingly becoming a trusted platelet activator for leading researchers around the world, and we’re delighted to highlight the innovative work it helps make possible.

This week we want to share the following work by Professor Gawaz and his team at the Hospital of the University of Tübingen: Effect of phosphodiesterase inhibitors on platelet function.

Hypothesis: PDE2, PDE3 and PDE5 display differential effects on platelet-mediated thrombosis.

Methods: Compare the effects of PDE inhibition by Ibudilast, a non-selective inhibitor of several PDEs with preference towards PDE3, PDE4, PDE10 and PDE11, IBMX, a nonspecific PDE inhibitor and Sildenafil, a potent selective PDE5 inhibitor, respectively, on platelet activation, aggregation and thrombus formation.

How CRP-A was used: CRP-A was used to induce GPVI-mediated platelet activation, aggregation and thrombus formation.

Key Findings: Platelet activation by ADP via P2Y12 and TRAP6 via PAR1 showed a greater response to PDE inhibitors than platelet activation by CRP-A via GPVI”

Title: Effect of phosphodiesterase inhibitors on platelet function

Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz

Read the Full Article on Biochemistry and Biophysics Reports

Ed Shovelin: PDE Inhibitors Preferentially Affect ADP and TRAP6 Activation